KB-141
KB-141 is a selective thyroid hormone receptor beta (TRβ) agonist that has been investigated for its potential therapeutic effects in treating metabolic disorders such as hyperlipidemia and obesity.
Mechanism of Action[edit | edit source]
KB-141 functions by selectively activating the thyroid hormone receptor beta (TRβ), which is predominantly expressed in the liver and other tissues involved in metabolism. This selectivity is significant because it allows for the modulation of metabolic processes without the cardiac side effects typically associated with non-selective thyroid hormone receptor activation, which also affects the thyroid hormone receptor alpha (TRα) found in the heart.
Therapeutic Potential[edit | edit source]
The primary therapeutic potential of KB-141 lies in its ability to lower cholesterol levels and reduce body weight. By activating TRβ, KB-141 enhances the metabolic rate, leading to increased energy expenditure and lipid metabolism. This makes it a promising candidate for the treatment of conditions like dyslipidemia and non-alcoholic fatty liver disease (NAFLD).
Clinical Trials[edit | edit source]
As of the latest updates, KB-141 has undergone several phases of clinical trials to evaluate its efficacy and safety profile. Early trials have shown promising results in terms of lipid-lowering effects and weight reduction, with a favorable safety profile due to its selective action on TRβ.
Side Effects[edit | edit source]
The side effects of KB-141 are generally mild and are primarily related to its metabolic effects. Common side effects include increased appetite, mild gastrointestinal disturbances, and transient increases in liver enzymes. However, due to its selective action, it avoids the cardiac side effects associated with non-selective thyroid hormone receptor agonists.
Research and Development[edit | edit source]
KB-141 is still under investigation, and ongoing research aims to further elucidate its long-term effects and potential applications in other metabolic disorders. Researchers are also exploring its combination with other therapeutic agents to enhance its efficacy and broaden its therapeutic scope.
Also see[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
